Front. Pharmacol.
Frontiers in Pharmacology
Front. Pharmacol.
1663-9812
Frontiers Media S.A.
1092147
10.3389/fphar.2022.1092147
Pharmacology
Erratum
Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
Frontiers Production Office
10.3389/fphar.2022.1092147
Frontiers Production Office
*
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
22
11
2022
2022
13
1092147
07
11
2022
07
11
2022
Copyright © 2022 Frontiers Production Office.
2022
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
An Erratum on Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab by Jiang F, Li J, Kong X, Sun P and Qu H (2022). Front. Pharmacol. 13:973448. doi: 10.3389/fphar.2022.973448
anlotinib
non-small cell lung cancer (NSCLC)
bevacizumab
efficacy
safety
Due to a mistake on the publisher’s part, this article was originally published as a Systematic Review instead of Original Research.
The publisher apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.